Behance Facebook Instagram Linkedin Twitter Vimeo VKontakte Youtube
Sign in
  • Home
  • Biotech News
  • Conferences
    • Gold Conferences
    • Biotech Conferences
    • Technology Conferences
  • CoronaVirus
    • Precision Vaccinations
  • Internet News
  • Research
  • Reverse Splits
    • Reverse Split News
    • Reverse Split Watch List
    • Reverse Stock Split List
    • Upcoming Reverse Stock Split List
  • More Finance Channels
    • Beverage Stocks
    • Blockchain Stocks
    • Gold Stocks
    • Marijuana Stocks
    • Psychedelic Stocks
    • Stand Down – Wall Street Bears
    • Tiki Hut Fund
Sign in
Welcome!Log into your account
Forgot your password?
Privacy Policy
Password recovery
Recover your password
Search
Monday, June 22, 2026
  • Sign in / Join
  • Contact Us
  • Featured News
  • Free Weekly Newsletter
Behance Facebook Instagram Linkedin Twitter Vimeo VKontakte Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Internet | Biotech Stock Review
  • Home
  • Biotech News
  • Conferences
    • Gold Conferences
    • Biotech Conferences
    • Technology Conferences
  • CoronaVirus
    • Precision Vaccinations
  • Internet News
  • Research
  • Reverse Splits
    • Reverse Split News
    • Reverse Split Watch List
    • Reverse Stock Split List
    • Upcoming Reverse Stock Split List
  • More Finance Channels
    • Beverage Stocks
    • Blockchain Stocks
    • Gold Stocks
    • Marijuana Stocks
    • Psychedelic Stocks
    • Stand Down – Wall Street Bears
    • Tiki Hut Fund
Home Biotech News 2020 Watch List Dyadic (DYAI) Price Target $12.
Dyadic, Biotech Stock Review
  • Biotech News
  • 2020 Watch List
  • All News
  • Client
  • CoronaVirus
  • Research
  • Superbug News - CoronaVirus Watch List

Dyadic (DYAI) Price Target $12.

By
Editor / Curator
-
November 6, 2020
Facebook
Twitter
Pinterest
Linkedin
Email
    • TAGS
    • DYAI
    Facebook
    Twitter
    Pinterest
    Linkedin
    Email
      Previous articleDalrada (DFCO) Removes Shell Company Status.
      Next articleAdding Galaxy Digital (GLXY) $5.19 to Watch List.
      Editor / Curator
      Editor / Curator

      RELATED ARTICLESMORE FROM AUTHOR

      All News

      Fusion Energy Starter.

      2026 Biotech 12 Pack

      We’re Up 360% in Six Weeks. Replimune (REPL).

      2026 Biotech 12 Pack

      GeoVax (GOVX) Conference Call and Transcript.

      All News

      Sekur Private Data (SWISF) Awarded Distribution Agreement With Elyon International.

      All News

      Broker Dealer – AtlasClear (ATCH) Conference Call

      2026 Biotech 12 Pack

      GeoVax (GOVX) Monkeypox (MPOX) PowerPoint.

      Reverse Stock Split, Watch List

      Plan Your Day Wisely

      June 2026
      M T W T F S S
      1234567
      891011121314
      15161718192021
      22232425262728
      2930  
      « May    

      AI Powered Biotech Research Tool

      Reverse Stock Split News

      Institutional Gold Research

      Latest article

      Fusion Energy Starter.

      All News Editor / Curator - June 22, 2026
      VC-Funded Fusion Energy Companies "The fastest way to deploy fusion and I believe one of my forecasts is we will replace every coal and natural...

      Party Time at UniQure (QURE)! From $8.86 to $47.21, up 432%.

      Uncategorized Editor / Curator - June 18, 2026
      I. No Bells, No Baskets. UniQure (QURE) $47 up Huge. Still Not Out Of The Woods! II. Replimune (REPL) $11.23. Gains 28% in Sympathy with...

      We’re Up 360% in Six Weeks. Replimune (REPL).

      2026 Biotech 12 Pack Editor / Curator - June 8, 2026
      That's a Gain of $604 Million, and That Ain't Bad! Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...
      Revelers.IO Finance Channel
      The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
      Contact us: roland@institutionalanalyst.com
      • Model Portfolio
      • Disclaimer
      • Contact us
      • Write For Us
      © Managed by Revelers.IO Media Group Inc.